Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously tre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://ncbi.nlm.nih.gov/pubmed/30316010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.10.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados